MUMBAI, India, November 4, 2011 /PRNewswire/ --
SCRIP, a leading global pharmaceutical and biotech news publication, honoured Glenmark with two global recognitions, for its business excellence and innovative R & D capabilities. At a glittering ceremony in London which was attended by the Who's Who of the world pharmaceutical industry on November 3; Glenmark was presented with 'Best Company in Emerging Markets' & 'Best Overall Pipeline' recognitions for the year 2011.
"On behalf of our 8000 employees worldwide, we are honoured to receive two prestigious distinctions from a reputed organisation like Informa Healthcare, which hosts the SCRIP Awards," said Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals Limited, who received the awards on behalf of the company. "We are specially delighted at having bagged the 'Best Overall Pipeline' distinction which is a testimony of our world-class R&D capabilities and an enormous tribute to all our research staff around the world who have committed themselves over many years to the development of our innovative pipeline," he added.
For SCRIP Awards 2011, Glenmark was the only company worldwide to be shortlisted under four categories. 'Executive of the Year - Glenn Saldanha' and 'Licensing Deal of the Year - GBR 500' were the other 2 categories, where Glenmark was nominated for this year's awards.
While announcing the nominations for Glenmark; SCRIP magazine commented:
- "Glenmark is a leader among the emerging market companies in drug discovery and development and most of its active substances in the pipeline are first-in-Class." *1
- "Glenmark's achievements over the year included a major deal with Sanofi in Crohn's disease, completing Phase III trials of its first novel product, crofelemer and demonstrated higher sales and profit growth."*2
* 1 SCRIP magazine issue dated Sep 23, 2011 * 2 SCRIP magazine issue dated Sep 16, 2011
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is a leading player in the discovery of new molecules, both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has eight molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis, IBD, etc.] and Pain [neuropathic pain and inflammatory pain].
SOURCE Glenmark Pharmaceuticals Ltd.